Next Article in Journal
A New Promising Anti-Infective Agent Inhibits Biofilm Growth by Targeting Simultaneously a Conserved RNA Function That Controls Multiple Genes
Previous Article in Journal
The Role of Subinhibitory Concentrations of Daptomycin and Tigecycline in Modulating Virulence in Staphylococcus aureus
Previous Article in Special Issue
New Antimicrobial Bioactivity against Multidrug-Resistant Gram-Positive Bacteria of Kinase Inhibitor IMD0354
Open AccessArticle

Screening of an FDA-Approved Library for Novel Drugs against Y. pestis

Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, 24 Reuven Lerer, Ness Ziona 74010001, Israel
*
Author to whom correspondence should be addressed.
Antibiotics 2021, 10(1), 40; https://doi.org/10.3390/antibiotics10010040
Received: 15 December 2020 / Revised: 29 December 2020 / Accepted: 30 December 2020 / Published: 3 January 2021
(This article belongs to the Special Issue Antibacterial Drug Discovery)
Yersinia pestis is a Gram-negative pathogen that causes plague, a devastating disease that kills millions worldwide. Although plague is efficiently treatable by recommended antibiotics, the time of antibiotic therapy initiation is critical, as high mortality rates have been observed if treatment is delayed for longer than 24 h after symptom onset. To overcome the emergence of antibiotic resistant strains, we attempted a systematic screening of Food and Drug Administration (FDA)-approved drugs to identify alternative compounds which may possess antibacterial activity against Y. pestis. Here, we describe a drug-repurposing approach, which led to the identification of two antibiotic-like activities of the anticancer drugs bleomycin sulfate and streptozocin that have the potential for designing novel antiplague therapy approaches. The inhibitory characteristics of these two drugs were further addressed as well as their efficiency in affecting the growth of Y. pestis strains resistant to doxycycline and ciprofloxacin, antibiotics recommended for plague treatment. View Full-Text
Keywords: Y. pestis; plague; repurposing; antibacterial; antibiotic resistance; FDA-approved drugs Y. pestis; plague; repurposing; antibacterial; antibiotic resistance; FDA-approved drugs
Show Figures

Figure 1

MDPI and ACS Style

Gur, D.; Chitlaru, T.; Mamroud, E.; Zauberman, A. Screening of an FDA-Approved Library for Novel Drugs against Y. pestis. Antibiotics 2021, 10, 40. https://doi.org/10.3390/antibiotics10010040

AMA Style

Gur D, Chitlaru T, Mamroud E, Zauberman A. Screening of an FDA-Approved Library for Novel Drugs against Y. pestis. Antibiotics. 2021; 10(1):40. https://doi.org/10.3390/antibiotics10010040

Chicago/Turabian Style

Gur, David; Chitlaru, Theodor; Mamroud, Emanuelle; Zauberman, Ayelet. 2021. "Screening of an FDA-Approved Library for Novel Drugs against Y. pestis" Antibiotics 10, no. 1: 40. https://doi.org/10.3390/antibiotics10010040

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop